A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

Exclusion Criteria

• •Participation in another clinical trial where investigational drug was received and last investigations within the last 8 weeks;
• •Clinically significant abnormal standard ECG at screening;
• •Clinically relevant and uncontrolled respiratory, cardiac, hepatic, gastrointestinal, renal, endocrine, metabolic, neurologic, or psychiatric disorders that may interfere with successful completion of this protocol;
• •Subjects with medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that in the opinion of the investigator would prevent use of anticholinergic;
• •Subjects with history of breathing problems (i.e., history of asthma including childhood asthma);
• •Positive urine test for cotinine;
• •Intake of non-permitted concomitant medications in the predefined period prior to screening or prior to randomization, or the subject is expected to take non-permitted concomitant medications during the study;
• •Presence of any current infection, or previous infection that resolved less than 7 days prior to screening or to randomization;
• •Known intolerance and/or hypersensitivity to any of the excipients contained in the formulation used in the trial;
• •Women who are pregnant or lactating;
• •Use of any kind of smoking electronic devices within 6 months before Screening.